Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.
We hypothesized that specific activation of a single retinoic acid receptor-alpha (RARalpha), without direct and concurrent activation of RARbeta and gamma, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer. A total of 50 uniparous mouse mammary tumor virus (MMTV)-neu and 50 nuliparous MMTV-wnt1 transgenic mice were treated with RARalpha agonist (retinobenzoic acid, Am580) that was added to the diet for 40 (neu) and 35 weeks (wnt1), respectively. Among the shared antitumor effects was the inhibition of epithelial hyperplasia, a significant increase (P<0.05) in tumor-free survival and a reduction in tumor incidence and in the growth of established tumors. In both models, the mechanisms responsible for these effects involved inhibition of proliferation and survival pathways, and induction of apoptosis. The treatment was more effective in the MMTV-wnt1 model in which Am580 also induced differentiation, in both in vivo and three-dimensional (3D) cultures. In these tumors Am580 inhibited the wnt pathway, measured by loss of nuclear beta-catenin, suggesting partial oncogene dependence of therapy. Am580 treatment increased RARbeta and lowered the level of RARgamma, an isotype whose expression we linked with tumor proliferation. The anticancer effect of RARalpha, together with the newly discovered pro-proliferative role of RARgamma, suggests that specific activation of RARalpha and inhibition of RARgamma might be effective in breast cancer therapy.
Lu
Y
Y
Division of Hematology-Oncology, Department of Medicine, Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY, USA.
Bertran
S
S
Samuels
T-A
TA
Mira-y-Lopez
R
R
Farias
E F
EF
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001565:Benzoates / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002472:Cell Transformation, Viral / Q000235:genetics; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics* / Q000502:physiology*; D051379:Mice; D008822:Mice, Transgenic; D009857:Oncogenes / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D018168:Receptors, Retinoic Acid / Q000819:agonists*; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes / Q000494:pharmacology* / Q000627:therapeutic use; D051155:Wnt1 Protein / Q000235:genetics*
D000970:Antineoplastic Agents; D001565:Benzoates; D018719:Erb-b2 Receptor Tyrosine Kinases; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes; D051155:Wnt1 Protein; C000607071:RARA protein, human; C000607072:Rara protein, mouse; C068073:Am 580
Nat Cell Biol. 2001 Sep;3(9):793-801
11533658
Cell. 2006 Nov 3;127(3):469-80
17081971
J Biol Chem. 1997 Jul 25;272(30):18538-41
9228017
N Engl J Med. 1993 Jul 15;329(3):177-89
8515790
Curr Opin Hematol. 2008 Jul;15(4):346-51
18536573
Cancer Invest. 2003 Apr;21(2):304-12
12743994
J Natl Cancer Inst. 1995 Nov 15;87(22):1655-7
7473809
J Biol Chem. 2002 Jul 12;277(28):24859-62
12032135
Genes Dev. 2000 Aug 1;14(15):1837-51
10921899
Br J Cancer. 2001 Aug 17;85(4):630-5
11506507
Science. 2004 Mar 5;303(5663):1483-7
15001769
EMBO J. 2002 Jul 1;21(13):3402-13
12093741
Mol Cell Biol. 2001 Feb;21(3):893-901
11154276
J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):119-31
15300008
Cell. 2007 Jun 15;129(6):1097-110
17574023
Biochem Pharmacol. 2008 Mar 1;75(5):1129-60
18164278
J Med Chem. 1988 Nov;31(11):2182-92
3184125
Science. 1987 Jan 9;235(4785):177-82
3798106
PPAR Res. 2007;2007:73256
18274629
J Exp Med. 1925 Nov 30;42(6):753-77
19869087
Mol Pharmacol. 1991 Oct;40(4):556-62
1656191
Cancer Res. 2000 Oct 1;60(19):5479-87
11034091
Mol Pharmacol. 2005 May;67(5):1808-17
15703382
Fed Proc. 1976 May 1;35(6):1332-8
770206
Cell. 1988 Jul 1;54(1):105-15
2898299
Mol Cancer. 2008 Nov 06;7:83
18990230
Br J Cancer. 1998;77(1):26-32
9459142
J Clin Oncol. 2001 Jun 15;19(12):3010-7
11408495
Curr Biol. 1999 Dec 2;9(23):1415-8
10607566
Gene. 2000 Apr 18;247(1-2):1-15
10773440
Methods. 2003 Jul;30(3):256-68
12798140
J Exp Med. 2006 May 15;203(5):1283-93
16682494
Breast Cancer Res. 2008;10(5):R82
18826564
Endocr Rev. 2005 Dec;26(7):898-915
16126938
Methods Enzymol. 1990;190:395-406
2087191
Nutr Rev. 1978 Jan;36(1):16-9
342996
Nutr Rev. 2000 Jul;58(7):211-4
10941258
FASEB J. 1996 Jul;10(9):940-54
8801176
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6
10759547
Cell. 2007 May 18;129(4):723-33
17512406
Biochem Biophys Res Commun. 1990 Nov 30;173(1):339-45
2175182
Biochemistry. 2007 Nov 27;46(47):13461-7
17983246
Tissue Eng Part C Methods. 2008 Dec;14(4):353-8
18800876
Oncogene. 2000 Feb 21;19(8):1038-44
10713687
J Cell Physiol. 2008 Nov;217(2):558-68
18615582
J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):323-35
18651209
Cancer Res. 2006 Apr 15;66(8):4240-8
16618747
J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):105-22
10219910
Am J Hematol. 2002 May;70(1):39-47
11994980
Apoptosis. 2001 Oct;6(5):377-88
11483862
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8
14668450
N Engl J Med. 1990 Sep 20;323(12):795-801
2202902
J Clin Pharm Ther. 2008 Aug;33(4):331-8
18613850
Cell. 1988 Nov 18;55(4):619-25
3180222
J Pathol. 2000 Jan;190(1):15-9
10640987